Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 4:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 726 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adenocarcinoma of the Prostate Clear all
Recruiting No phase listed Observational

A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies

NCT04923178
View directory record Official record
Conditions
Urothelial Cancer, Bladder Cancer, Genitourinary Cancer, Urogenital Neoplasms, Urogenital Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2042
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 14, 2026, 4:59 PM EDT
Terminated Phase 1 Interventional

Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer

NCT00512668
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Interventions
leuprolide acetate, goserelin acetate, bicalutamide, nilutamide, flutamide, temsirolimus, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Oct 14, 2026, 4:59 PM EDT
Terminated Phase 1 Interventional

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

NCT04249947
View directory record Official record
Conditions
Prostatic Neoplasms, Castration-Resistant, Neoplasms by Histologic Type, Neoplasms, Prostate, Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Neoplasms, Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Neoplasms by Site, Prostatic Disease, Salivary Gland Cancer, Salivary Gland Tumor, Adenoid Cystic Carcinoma, Salivary Duct Carcinoma, Mucoepidermoid Carcinoma, Acinic Cell Tumor
Interventions
P-PSMA-101 CAR-T cells, Rimiducid
Biological · Drug
Lead sponsor
Poseida Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
10
States / cities
Duarte, California • San Diego, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 14, 2026, 4:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy

NCT01083368
View directory record Official record
Conditions
Prostate Cancer
Interventions
temsirolimus, bevacizumab, polymorphism analysis, laboratory biomarker analysis
Drug · Biological · Genetic + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Cleveland, Ohio • Willoughby Hills, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 14, 2026, 4:59 PM EDT
Completed Phase 2 Interventional

Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate

NCT00083005
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, estramustine phosphate sodium, thalidomide
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 14, 2026, 4:59 PM EDT
Completed Phase 2 Interventional

Soy Isoflavones in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage I or Stage II Adenocarcinoma of the Prostate

NCT00078923
View directory record Official record
Conditions
Prostate Cancer
Interventions
soy isoflavones, neoadjuvant therapy, Placebo
Dietary Supplement · Procedure · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Oct 14, 2026, 4:59 PM EDT
Active, not recruiting Phase 2 Interventional

Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

NCT02703623
View directory record Official record
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Abiraterone Acetate, Apalutamide, Cabazitaxel, Carboplatin, Ipilimumab, Laboratory Biomarker Analysis, Prednisone
Drug · Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
3
States / cities
Houston, Texas • Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 14, 2026, 4:59 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Xyotax to Treat Prostate Cancer

NCT00446836
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Paclitaxel polyglumex (Xyotax)
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 14, 2026, 4:59 PM EDT
Not listed Phase 1Phase 2 Interventional

Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

NCT00002775
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, estramustine phosphate sodium
Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 14, 2026, 4:59 PM EDT
Completed Phase 2 Interventional

A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma

NCT04090775
View directory record Official record
Conditions
Metastatic Prostatic Adenocarcinoma
Interventions
Opdivo Injectable Product, Yervoy Injectable Product, Cytoxan, Cryosurgical freezing (cryosurgery)
Drug · Procedure
Lead sponsor
Rampart Health, L.L.C.
Industry
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Lancaster, California • Rochester, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 14, 2026, 4:59 PM EDT
Terminated Phase 1 Interventional

Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.

NCT05276492
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm, Prostate Cancer Metastatic
Interventions
Abiraterone Oral Tablet, Prednisone tablet, Drug Dairy/Log, Low-fat meal
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 14, 2026, 4:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy

NCT00331344
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
mitoxantrone hydrochloride, ixabepilone, prednisone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
San Francisco, California • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Oct 14, 2026, 4:59 PM EDT
Active, not recruiting Not applicable Interventional

A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer

NCT05027477
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Radical Prostatectomy, TULSA Procedure
Device
Lead sponsor
Profound Medical Inc.
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2036
U.S. locations
19
States / cities
Chandler, Arizona • Mesa, Arizona • Scottsdale, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 14, 2026, 4:59 PM EDT
Terminated Phase 2 Interventional

Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)

NCT00005039
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
recombinant fowlpox-prostate specific antigen vaccine, recombinant vaccinia prostate-specific antigen vaccine, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 14, 2026, 4:59 PM EDT
Completed Phase 3 Interventional Results available

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

NCT03274687
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
Interventions
Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Radiation Therapy
Radiation · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
229
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 188 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 14, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen

NCT00715078
View directory record Official record
Conditions
Prostate Cancer
Interventions
sipuleucel-T
Biological
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
12
States / cities
La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 14, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer

NCT03830164
View directory record Official record
Conditions
Male Erectile Disorder, Prostate Adenocarcinoma, Erectile Dysfunction, CTCAE, Impotence
Interventions
Atorvastatin, Pentoxifylline, Vitamin E Compound
Drug · Dietary Supplement
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 14, 2026, 4:59 PM EDT
Terminated Phase 2 Interventional

Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer

NCT03360721
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma Without Neuroendocrine Differentiation, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate, Apalutamide, Prednisone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 14, 2026, 4:59 PM EDT
Recruiting Phase 1 Interventional

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

NCT06778863
View directory record Official record
Conditions
Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Lung Cancer, Ovarian Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Bladder Cancer
Interventions
CLSP-1025
Drug
Lead sponsor
Clasp Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
21
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 14, 2026, 4:59 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer

NCT07192614
View directory record Official record
Conditions
Prostate Cancer
Interventions
AZD6621
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Orlando, Florida • Tampa, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 14, 2026, 4:59 PM EDT
Recruiting Phase 2 Interventional

A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer

NCT05751434
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Localized Prostate Carcinoma
Interventions
Exercise Therapy
Behavioral
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
10
States / cities
Durate, California • Los Angeles, California • Hartford, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 14, 2026, 4:59 PM EDT
Completed Phase 2 Interventional

Hormone Therapy in Treating Patients With Prostate Cancer

NCT00003323
View directory record Official record
Conditions
Prostate Cancer, Sexual Dysfunction and Infertility
Interventions
finasteride, flutamide, quality-of-life assessment
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Male only
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2010
U.S. locations
43
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2016 · Synced Oct 14, 2026, 4:59 PM EDT
Terminated Phase 2 Interventional Results available

Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel

NCT01253642
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Metastatic Prostatic Adenocarcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Interventions
Biopsy of Prostate, Docetaxel, Laboratory Biomarker Analysis, Phenelzine Sulfate
Procedure · Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
3
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 14, 2026, 4:59 PM EDT
Completed Not applicable Interventional

Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer

NCT02163317
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
Interventions
stereotactic radiosurgery, magnetic resonance imaging, quality-of-life assessment, Serum Prostate Antigen Test, Digital Rectal Exam, Expanded Prostate Cancer Index Composite
Radiation · Device · Other + 2 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 14, 2026, 4:59 PM EDT